The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma – a single-center analysis

Abstract

Patients with primary gastrointestinal (GI) lymphoma are at risk of GI perforations. Therefore, we aimed to investigate the prognostic impact of non-traumatic GI perforations. 54 patients with a histologically confirmed diagnosis of primary GI lymphoma were included. Non-traumatic lymphoma perforation occurred in ten patients (19%). Perforations occurred only in patients with aggressive B-cell lymphoma. In patients with aggressive B-cell lymphoma, the median overall survival (mOS) was 52 months (95% CI 9.88–94.12) and 27 months (95% CI 0.00–135.48) in patients with and without GI perforation, respectively. The median progression-free survival (mPFS) was 30 months (95% CI 5.6–54.4) in patients with GI perforations. In patients without lymphoma perforation, mPFS was not reached. Both mOS and mPFS did not significantly differ. In conclusion, despite the need for emergency surgery and delay in lymphoma-directed treatment, lymphoma perforation did not negatively impact our study population’s OS or PFS.

Keywords:

• Primary gastrointestinal lymphoma
• gastric perforation
• intestinal perforation
• aggressive B-NHL

Disclosure statement

F.M. received support for meeting attendance from Servier, AbbVie, Incyte, Gilead, Jazz Pharmaceuticals, Novartis, Teva, Pfizer and Amgen, received support for medical writing from Servier and Springer Verlag, received research grants from Apis Technologies, Daiichi Sankyo and received speaker honoraria from Servier, Jazz Pharmaceuticals, and AbbVie; C.B. received honoraria from Merck KGaA, Sanofi, Roche, Bayer, Bristol-Myers Squibb, AstraZeneca, Merck Sharp Dohme, Medac, Hexal, Med Update GmbH, I Med Institute, participated in advisory boards for Sanofi, Bayer Schering Pharma, Merck Sharp & Dohme, GSO, AOK Health Insurance, ODC (Oncology drug consultant), Janssen-Cilag GmbH, BioNTech SE, received research funding from AbbVie, ADC Therapeutics, Agile Therapeutics, Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, BerGenBio, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eisai, Gilead Sciences, Glycotope GmbH, GlaxoSmithKline, Incyte, IO Biotech, Isofol Medical, Janssen-Cilag, Karyopharm Therapeutics, Lilly, Millennium, MSD, Nektar, Novartis, Rafael Pharmaceuticals, Roche, Springworks Therapeutics, Taiho Pharmaceutical, Ipsen, Servier, Pfizer, Immatics, CPT Cellex Patient Treatment, Glycostern, BioNTech SE, and received travel accommodations from Merck Serono, Sanofi, Bristol-Myers Squibb, Janssen-Cilag, and Daiichi Sankyo; W.F. participated in advisory boards for Morphosys, AbbVie, Pfizer, Amgen, Jazz Pharmaceuticals, and Clinigen, received support for meeting attendance from Amgen, Jazz Pharmaceuticals, Daiichi Sankyo Oncology, Bristol Myers Squibb, and Servier, received support for medical writing from Amgen, Boehringer Ingelheim, Pfizer, and AbbVie, and received research funding from Apis Technologies; P.A., PH.K., S.W., J.D., and S.G. have nothing to declare.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.